

Dual Advanced Therapy for Crohn's Disease - Criteria for use

There is local agreement that dual advanced treatment below may be considered within the agreed criteria below for refractory Crohn's disease where combined mechanisms of action may be more effective.

- Anti-TNF (adalimumab/IV infliximab) + vedolizumab
- Anti-TNF (adalimumab/IV infliximab) + ustekinumab
- Anti-TNF (adalimumab/IV infliximab) + risankizumab
- Ustekinumab + upadacitinib
- Ustekinumab + vedolizumab

The most cost-efficient combinations should ideally be used according to patient characteristics/treatment history. Where more than one combination is suitable then the lowest cost option should be chosen, for example the combination of ustekinumab with an anti-TNF is preferred over risankizumab and an anti-TNF.

Criteria for use

All of the following criteria must apply for combination use:

- Refractory Crohn's disease requiring two mechanisms of action (refer to Section 1)
- Consensus decision to treat at biologics multidisciplinary team meeting
- Disease progression (defined by cross-sectional imaging and endoscopy) despite optimised treatment as describe below
- Inadequate response with, lost response to, or were intolerant to vedolizumab, ustekinumab or risankizumab and upadacitinib and a TNF-alpha inhibitor or have medical contraindications to such therapies.
- Surgical treatment inappropriate
- Inclusion of the patient in clinical trials has been considered but is unsuitable

Response

- A 6 month assessment of disease activity after initiation will be reviewed to determine if continuation of treatment is appropriate taking into account disease activity score, biochemistry (including C-reactive protein and faecal calprotectin) and endoscopic assessment or cross sectional imaging.
- Improvement in physician's global assessment grading from severe to moderate disease is an acceptable response.

Stopping criteria

- If there is no improvement after six months discontinuation of therapy should be considered.

Safety considerations

- The limited case series published suggest dual biologic therapy is well tolerated and does not signal a strong safety concern. Additionally dual biologic therapy has been occurring for several years in other indications with no safety issues identified
- Patients will be closely monitored and any safety concerns will be reported

South East London Integrated Medicines Optimisation Committee (SEL IMOC). A partnership between NHS organisations in South East London Integrated Care System: NHS South East London (covering the boroughs of Bexley, Bromley, Greenwich, Lambeth, Lewisham and Southwark) and GSTFT/KCH /SLaM/ Oxleas NHS Foundation Trusts/Lewisham & Greenwich NHS Trust

Date produced: March 2022 Last updated & approved: September 2025 Next date for review September 2027 (or sooner if evidence or practice changes)

Not to be used for commercial or marketing purposes. Strictly for use within the NHS.

Suggested approach to monitoring implementation and outcomes

- A database of these patients will be maintained to track patient outcomes, safety and adherence to include criteria
- Patients will be monitored closely at fixed intervals, as outlined above
- Data and usage will be presented at the IBD group

References

1. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398–405.
2. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876–85
3. Yarur AJ, Kanagala V, Stein DJ, et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease. Aliment Pharmacol Ther 2017;45:933–40.
- Davidov Y, Ungar B, Bar-Yoseph H, et al. Association of induction infliximab levels with clinical response in perianal Crohn's disease. J Crohns Colitis 2017;11:549–55